And Quiet Flows the Don¹: A (possibly) divided government investor playbook, and the Pfizer vaccine news

Well, it happened: absent unexpected reversals from state recounts or from the Courts (see our note on election litigation last Friday), for the first time in 100 years, a challenger unseated an incumbent President at a time of strong economic and market tailwinds (see p.5). The rarity of such an outcome tells you how hard this is to accomplish. However, when looking at the full scope of Federal and state results, the election delivered a clearer referendum on the President himself² than on policy issues dividing Democrats and Republicans. Why is that? The chart below shows partisan control of the Senate, the House, Gubernatorial positions and State-level Senates and Houses (i.e., state legislatures). Forget about a “Blue Wave”: according to our Partisan Balance index³, the Democratic tide actually went out a little bit, falling relative to pre-election levels.

The chart illustrates the major party shifts in the 20th and 21st centuries: the decline in the Democratic share from its enormous level during the Great Depression; Eisenhower’s popularity in a country not yet ready for Adlai Stevenson’s liberalism; the two big post-war Democratic waves during the JFK/LBJ Great Society era and the Nixon impeachment era; the GOP rebound following the Reagan Revolution in the 1980’s and Gingrich’s “Contract with America” in 1994; the powerful but very temporary Obama wave in 2009; and the anti-Trump reaction during the 2018 midterms.

Blue Wave? At the Federal and State level, the Democratic tide actually went out

Federal/State Partisan Balance Index, 1937-2021
% control of the House, Senate, Governorships, State Senates & State Houses by party

¹ “And Quiet Flows the Don” is an epic novel by Mikhail Sholokhov from the early 20th century, describing the lives of self-governing militarized Cossack populations living along the Don River during the Russian Civil War

² Was the Trump administration an actualization of what might have happened had Louisiana Senator Huey Long become President, if he had run against FDR in 1936 and won? Examples: a piece by Adrian Mercer on the LSE American Politics and Policy Blog in April 2018, a piece by Annika Nelson in The Atlantic in March 2019 and "The Demagogue’s Playbook" by Eric Posner at the University of Chicago, which compares Trump to Huey Long, as well as Andrew Jackson, Joseph McCarthy and George Wallace

³ Partisan Balance Index weights: Senate 25%, House 25%, Governorships 25% and State Senates and Houses 12.5% each. We assume that the partisan balance in the Senate is 51-49 in 2021 (i.e., NC/AK Senate seats go to the GOP, and the GOP wins one of the two Senate runoffs in Georgia), and that the balance in the House ends up at 223 DEM, 212 GOP once outstanding House elections are called and all vacancies are filled
As we explained on our webcast last week, a divided government would still give President Biden room to maneuver on energy, immigration, healthcare, trade, net neutrality and antitrust. However, while there might be some personal or corporate tax increases tacked on to an infrastructure bill, the huge tax/spending expansion that Biden ran on (see p.5) is probably off the table unless Democrats can pull off both victories in Georgia runoff elections, and unless Democrats decide to jettison the Senate filibuster despite not having a majority in the Senate (they would need to rely on VP Harris for tie-breakers). On page 5, we show the rising use of the Senate filibuster over the last century by both parties, which may explain the hesitance by some to scrap it.

Since July 2020, markets have been favoring our “Biden portfolio” of stocks and sectors, and punishing the “Trump portfolio”. If divided government becomes a reality, the path forward may benefit a “purple” mix of both. The sectors we feel strongest about owning: renewable energy, infrastructure stocks, tax cut beneficiary stocks (based on the 2017 tax bill), stocks with high levels of international exposure and banks. The sectors we would still be cautious about: China trade war stocks, and large cap pharma. Neutral: the Big 4 antitrust targets.

### Biden vs Trump portfolio performance

Jan 2020 = 100

**Renewable energy**: no Green New Deal, but the President can still increase the cost of capital on oil & gas by disallowing further LNG export permits, tightening fracking/methane rules (particularly on public lands), increasing climate risk disclosure requirements and reinstating automobile mileage standards which Trump softened last spring. Biden can also try to boost penetration of grid renewables through subsidies and Federal eminent domain decisions on HVDC transmission infrastructure for wind/solar projects. Remember as well that US states set their own renewable portfolio standards, they are not set at the national level

**Infrastructure**: if there’s one point of agreement between both parties, it’s the need for reinvestment in dilapidated US transportation, maritime and aerospace infrastructure; modest bipartisan bill possible in 2021

**China trade war**: Biden is likely to go very slow here, and is unlikely to remove Trump tariffs in his first 18 months, particularly since China is only 25%-45% compliant with Phase I trade deal purchases from the US. Anti-China policies are now firmly bipartisan, albeit for a mix of reasons (mercantilism and human rights). Rules requiring Chinese companies to delist from US exchanges for disclosure shortfalls will probably move forward, and Biden may be reluctant to remove any Chinese firms from the Commerce Department “Bad Actor” entity list (such firms are ineligible to purchase US exports, directly or through intermediaries). Note: Trump’s tariffs raised import prices on US firms and consumers but didn’t make money for the US government, since almost the entire tariff increase has been used to pay US farmers (as per Benn Steil at CFR)

**Companies with high international sales exposure and companies that benefited from the 2017 tax cuts**: more stimulus should boost the global economy in 2021, and a substantial US corporate tax hike is unlikely
Large cap pharma: bipartisan prescription drug bill is possible, and the Executive Branch can also implement demonstration projects that bring Medicare Part D drug prices down to international levels.

Antitrust targets (FB, AAPL, AMZN, GOOGL): the most punitive outcomes are probably off the table (i.e., those in the October House Judiciary report: “Glass-Steagall” legislation for tech, rules to prevent discrimination and self-preferencing, merger prohibition, prohibition on abuse of bargaining power, strengthening antitrust law). Even so, there’s still the Justice Dep’t case against Google, and a possible one pending vs Facebook.

Where to from here, for investors?

A client once asked me to compute the table below, which shows equity market returns broken down by Presidential and Congressional party permutation since 1945. The highest returns occurred during “gridlock” periods with a Democratic President, but I don’t think we should pay too much attention to these results. The sample sizes are very small, and the return differences largely reflect when recessions occurred and how the Fed reacted to them. Unless you think Presidents and Congress can cause recessions, and/or that they should get the credit for inheriting a recovery, these equity market returns by party affiliation are largely random.

Instead, let’s look at the business cycle: the US and Europe are in a race against time. US employment is improving: roughly half the increase in unemployment is permanent, but the other half is temporary. As the global recovery continues, we expect US unemployment of ~5% by the end of 2021. Another important sign: the number of unemployed people and job seekers relative to job openings is much lower than in prior recessions. That’s a sign that when/if COVID is conquered, there could be a strong and rapid further recovery in employment and wages. Based on the explosion of monetary and fiscal stimulus unleashed on the world in 2020 (see p.5), we expect the current recovery to continue into 2021.
However, the race against time is getting short: COVID infections, hospitalizations and deaths are rising again. This increases chances of lockdowns (which could jeopardize the employment and spending recovery), and highlights the importance of vaccine APPROVAL, DISTRIBUTION and ACCEPTANCE, three distinct hurdles to overcome on the road to herd immunity.

Pfizer reported 90% efficacy from its mRNA vaccine Phase III trials this morning (which my COVID science advisory group has not had time to fully dissect yet). That addresses the first hurdle, which is obviously a critical one; Pfizer expects to have Emergency Use Authorization by late November. Pfizer’s earlier Phase II results were similar to those reported by Oxford and Moderna, boding well for the possibility of additional vaccine approvals in the months ahead.

That leaves distribution, which is no small feat given the need for millions of vaccinations, cold storage at negative 94°F/-70°C (!!) and a booster shot 21 days later, and then acceptance. A September 2020 Pew Research poll found that only 51% of US respondents would get a COVID vaccine, while another September poll from USA Today found that only 27% of respondents would get a vaccine as soon as it became available. The US ranks in the lower third globally on the issue of vaccine acceptance and trust in science, as we have discussed in prior notes. Greater adherence to scientific principles in Washington can only help, as could a decision by Trump not to fire Dr. Fauci, who has served in his NIAID role since 1984. And on herd immunity, don’t hold your breath: as shown below, most US states are still long, long way off.

**United States virus tracking**

Current hospitalizations and daily infections

<table>
<thead>
<tr>
<th>Date</th>
<th>New daily infections (LHS)</th>
<th>Cur Hosp (LHS)</th>
<th>Daily deaths (RHS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3/14</td>
<td>120,000</td>
<td>100,000</td>
<td>2,500</td>
</tr>
<tr>
<td>4/13</td>
<td>110,000</td>
<td>90,000</td>
<td>2,000</td>
</tr>
<tr>
<td>5/13</td>
<td>100,000</td>
<td>80,000</td>
<td>1,500</td>
</tr>
<tr>
<td>6/12</td>
<td>90,000</td>
<td>70,000</td>
<td>1,000</td>
</tr>
<tr>
<td>7/12</td>
<td>80,000</td>
<td>60,000</td>
<td>500</td>
</tr>
<tr>
<td>8/11</td>
<td>70,000</td>
<td>50,000</td>
<td>0</td>
</tr>
<tr>
<td>9/10</td>
<td>60,000</td>
<td>40,000</td>
<td>0</td>
</tr>
<tr>
<td>10/10</td>
<td>50,000</td>
<td>30,000</td>
<td>0</td>
</tr>
<tr>
<td>11/9</td>
<td>40,000</td>
<td>20,000</td>
<td>0</td>
</tr>
</tbody>
</table>

Source: COVID Tracking Project, JPMAM. 11/7/2020. 7 day avgs.

**CDC Vaccine Priority Groups**

1. **Healthcare personnel (~17-20mm):** Includes workers in hospitals, long-term care facilities, outpatient, home health care, pharmacies, EMS and public health
2. **Essential workers (~60-80mm):** Includes workers in food & agriculture, transportation, education, energy, water/wastewater and police/fire
3. **Adults ≥ 65 years old (~53mm):** Represents 16% of population; ~3mm live in long-term care facilities
4. **High risk medical conditions (>100mm):** Examples include obesity, diabetes, chronic obstructive pulmonary disease (COPD), heart conditions, chronic kidney disease
5. **Everyone else (around 50% of the population)**

**Estimated COVID prevalence by state as of early August 2020**

Percent, based on seroprevalence surveys

Source: CDC Nationwide Commercial Laboratory Seroprevalence Survey. August 1, 2020. *No seroprevalence data for HI, SD and WY.
Appendix charts: Presidential tailwind tracker, Biden’s proposed tax/spending agenda, the monetary/fiscal stimulus explosion in the wake of COVID, and the rising frequency of filibusters in the Senate

For the first time in 100 years, an incumbent with strong tailwinds lost the Presidency

Market/economic conditions at each election, derived from inflation, equities, employment, home prices and per capita GDP (higher score = more favorable conditions)

Sources: Home prices (S&P/Core Logic/Shiller/BLS); consumer and producer prices (BLS); US large cap equity returns and volatility (Shiller/Bloomberg); unemployment levels and changes (BLS, C. Romer/UC Berkeley); US per capita GDP vs G10 (Conference Board, Maddison/University of Groningen); JPMAM, 2020. Inflation percentiles based on deviation from target 2% level.

Biden Agenda: $3 trillion in taxes, $8 trillion in spending

$ trillion over 10 years

Entitlement expansion
Housing
Education
Infrastructure & Jobs
Healthcare
Drug price reforms
Industry specific taxes
Payroll tax >$400k
Corporate tax hikes
Taxes on the wealthy
Tax credits

$10
$8
$6
$4
$2
$0
-$2

Taxes on the wealthy
Industry specific taxes
Corporate tax hikes
Payroll tax >$400k
Base broadening
Tax credits


Debt monetization response to GVC eclipses everything else

Govt. fiscal deficits: change vs pre-crisis level, % of GDP

Central Bank balance sheets: change vs pre-crisis level, % of GDP


Cloture motions filed (motions to end debate)

Number of cloture motions filed, 65th Congress - 116th Congress

Cloture motions are a reasonable proxy for filibuster frequency. From 1917 to 1996, the correlation of cloture motions and documented filibusters was 0.94

Purpose of This Material: This material is for information purposes only. The views, opinions, estimates and strategies expressed herein constitute Michael Cembalest’s judgment based on current market conditions and are subject to change without notice, and may differ from those expressed by other areas of J.P. Morgan. This information in no way constitutes J.P. Morgan Research and should not be treated as such.

GENERAL RISKS & CONSIDERATIONS
Any views, strategies or products discussed in this material may not be appropriate for all individuals and are subject to risks. Investors may get back less than they invested, and past performance is not a reliable indicator of future results. Asset allocation / diversification does not guarantee a profit or protect against loss. Nothing in this material should be relied upon in isolation for the purpose of making an investment decision. You are urged to consider carefully whether the services, products, asset classes (e.g. equities, fixed income, alternative investments, commodities, etc.) or strategies discussed are suitable to your needs. You must also consider the objectives, risks, charges, and expenses associated with an investment service, product or strategy prior to making an investment decision. For this and more complete information, including discussion of your goals/situation, contact your J.P. Morgan team.

NON-RELIANCE
Certain information contained in this material is believed to be reliable; however, JPM does not represent or warrant its accuracy, reliability or completeness, or accept any liability for any loss or damage (whether direct or indirect) arising out of the use of all or any part of this material. No representation or warranty should be made with regard to any computations, graphs, tables, diagrams or commentary in this material, which are provided for illustration/reference purposes only. The views, opinions, estimates and strategies expressed in this material constitute our judgment based on current market conditions and are subject to change without notice. JPM assumes no duty to update any information in this material in the event that such information changes. Views, opinions, estimates and strategies expressed herein may differ from those expressed by other areas of JPM, views expressed for other purposes or in other contexts, and this material should not be regarded as a research report. Any projected results and risks are based solely on hypothetical examples cited, and actual results and risks will vary depending on specific circumstances. Forward-looking statements should not be considered as guarantees or predictions of future events.

Nothing in this document shall be construed as giving rise to any duty of care owed to, or advisory relationship with, you or any third party. Nothing in this material should be relied upon in isolation for the purpose of making an investment decision. For this and more complete information, including discussion of your goals/situation, contact your J.P. Morgan representative or appropriate J.P. Morgan office. You must also consider the objectives, risks, charges, and expenses associated with an investment service, product or strategy prior to making an investment decision. For this and more complete information, including discussion of your goals/situation, contact your J.P. Morgan office.

LEGAL ENTITY, BRAND & REGULATORY INFORMATION
In the United States, bank deposit accounts and related services, such as checking, savings and bank lending, are offered by JPMorgan Chase Bank, N.A. Member FDIC. JPMorgan Chase Bank, N.A. and its affiliates (collectively "JPMCB") offer investment products, which may include bank managed investment accounts and custody, as part of its trust and fiduciary services. Other investment products and services, such as brokerage and advisory accounts, are offered through J.P. Morgan Securities LLC ("JPMPS"), a member of FINRA and SIPC. Annuities are made available through Chase Insurance Agency, Inc. (CIA), a licensed insurance agency, doing business as Chase Insurance Agency Services, Inc. in Florida. JPMCB, JPMPS and CIA are affiliated companies under the common control of JPM. Products not available in all states.

In Luxembourg, this material is issued by J.P. Morgan Bank Luxembourg S.A. (JPMBL), with registered office at European Bank and Business Centre, 6 route de Trèves, L-2633, Senningerberg, Luxembourg. R.C.S Luxembourg B10.958. Authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg S.A. is authorized as a credit institution in accordance with the Law of 5th April 1993. In the United Kingdom, this material is issued by J.P. Morgan Bank Luxembourg S.A – London Branch. Prior to Brexit, Brexit meaning that the UK leaves the European Union under Article 50 of the Treaty on European Union, or, if later, loses its ability to passport financial services between the UK and the remainder of the EEA, J.P. Morgan Bank Luxembourg S.A – London Branch is subject to the Prudential Regulation Authority and the Prudential Regulation Authority. Details about the extent of our regulation by the Financial Conduct Authority and the Prudential Regulation Authority are available from us on request. In the event of Brexit, in the UK, J.P. Morgan Bank Luxembourg S.A – London Branch is authorised by the Prudential Regulation Authority, subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request. In Spain, this material is distributed by J.P. Morgan Bank Luxembourg S.A., Sucursal en España, with registered office at Paseo de la Castellana, 31, 28046 Madrid, Spain. J.P. Morgan Bank Luxembourg S.A., Sucursal en España is registered under number 1516 within the administrative registry of the Bank of Spain and supervised by the Spanish Securities Market Commission (CNMV). In Germany, this material is distributed by J.P. Morgan Bank Luxembourg S.A., Frankfurt Branch, registered office at Taunustor 1 (TaunusTurm), 60310 Frankfurt, Germany, jointly supervised by the Commission de Surveillance du Secteur Financier (CSSF) and the Japanese Financial Services Authority (JFSA). In the Netherlands, this material is distributed by J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch, with registered office at World Trade Centre, Tower 8, Scharnweerdelaan 1135, 1077 XX, Amsterdam, The Netherlands. J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch is authorised and regulated by the Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF in Luxembourg; J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch is also authorised and supervised by De Nederlandsche Bank (DNB) and the Autoriteit Financiële Markten (AFM) in the Netherlands. Registered with the Kamer van Koophandel as a branch of J.P. Morgan Bank Luxembourg S.A. under registration number 71651845. In Denmark, this material is distributed by J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A. with registered office at Kalvebod Brygge 39-41, 1560 København V, Denmark. J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A.is authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A. is also subject to the supervision of Finanstilsynet (Danish FSA) and registered with Finanstilsynet as a branch of J.P. Morgan Bank Luxembourg S.A. under code 29009. In Sweden, this material is distributed by J.P. Morgan Bank Luxembourg S.A. – Stockholm Bankfilial, with registered office at Hamngatan 15, Stockholm, 11147, Sweden. J.P. Morgan Bank Luxembourg S.A. – Stockholm Bankfilial is authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg S.A. – Stockholm Bankfilial is also subject to the supervision of Finansinspektionen (Swedish FSA). Registered with Finansinspektionen as a branch of J.P. Morgan Bank Luxembourg S.A. In France, this material is distributed by JPMorgan Chase Bank, N.A. ("JPMCB"), Paris branch, which is regulated by the French banking authorities Autorité de Contrôle Prudentiel et du Secteur Financier (ACPrFSF), Commission de Surveillance du Secteur Financier (CSSF) and the French Prudential Supervision Authority (Direction Générale de la Concurrence, de la Consommation et de la Répression des Fraudes – DGCCRF) or any other French banking or financial supervisory authority. J.P. Morgan Bank Luxembourg S.A. (JPMBL) is also authorized by De Nederlandsche Bank (DNB) and the Autoriteit Financiële Markten (AFM) in the Netherlands. Registered with the Kamer van Koophandel as a branch of J.P. Morgan Bank Luxembourg S.A. under registration number 71651845.
et de Résolution and Autorité des Marchés Financiers. In Switzerland, this material is distributed by J.P. Morgan (Suisse) SA, which is regulated in Switzerland by the Swiss Financial Market Supervisory Authority (FINMA).

In Hong Kong, this material is distributed by JPMCB, Hong Kong branch. JPMCB, Hong Kong branch is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission of Hong Kong. In Hong Kong, we will cease to use your personal data for our marketing purposes without charge if you so request. In Singapore, this material is distributed by JPMCB, Singapore branch. JPMCB, Singapore branch is regulated by the Monetary Authority of Singapore. Dealing and advisory services and discretionary investment management services are provided to you by JPMCB, Hong Kong/Singapore branch (as notified to you). Banking and custody services are provided to you by JPMCB Singapore Branch. The contents of this document have not been reviewed by any regulatory authority in Hong Kong, Singapore or any other jurisdictions. This advertisement has not been reviewed by the Monetary Authority of Singapore. JPMorgan Chase Bank, N.A., a national banking association chartered under the laws of the United States, and as a body corporate, its shareholder’s liability is limited.

JPMorgan Chase Bank, N.A. (JPMCBNA) (ABN 43 074 112 011/AFS Licence No: 238367) is regulated by the Australian Securities and Investment Commission and the Australian Prudential Regulation Authority. Material provided by JPMCBNA in Australia is to “wholesale clients” only. For the purposes of this paragraph the term “wholesale client” has the meaning given in section 761G of the Corporations Act 2001 (Cth). Please inform us if you are not a Wholesale Client now or if you cease to be a Wholesale Client at any time in the future.

JPM is a registered foreign company (overseas) (ARBN 109293610) incorporated in Delaware, U.S.A. Under Australian financial services licensing requirements, carrying on a financial services business in Australia requires a financial service provider, such as J.P. Morgan Securities LLC (JPMS), to hold an Australian Financial Services Licence (AFSL), unless an exemption applies. **JPMS is exempt from the requirement to hold an AFSL under the Corporations Act 2001 (Cth) (Act) in respect of financial services it provides to you, and is regulated by the SEC, FINRA and CFTC under US laws, which differ from Australian laws.** Material provided by JPMS in Australia is to “wholesale clients” only. The information provided in this material is not intended to be, and must not be, distributed or passed on, directly or indirectly, to any other class of persons in Australia. For the purposes of this paragraph the term “wholesale client” has the meaning given in section 761G of the Act. Please inform us immediately if you are not a Wholesale Client now or if you cease to be a Wholesale Client at any time in the future.

This material has not been prepared specifically for Australian investors. It:
- may contain references to dollar amounts which are not Australian dollars;
- may contain financial information which is not prepared in accordance with Australian law or practices;
- may not address risks associated with investment in foreign currency denominated investments; and
- does not address Australian tax issues.

With respect to countries in Latin America, the distribution of this material may be restricted in certain jurisdictions. We may offer and/or sell to you securities or other financial instruments which may not be registered under, and are not the subject of a public offering under, the securities or other financial regulatory laws of your home country. Such securities or instruments are offered and/or sold to you on a private basis only. Any communication by us to you regarding such securities or instruments, including without limitation the delivery of a prospectus, term sheet or other offering document, is not intended by us as an offer to sell or a solicitation of an offer to buy any securities or instruments in any jurisdiction in which such an offer or a solicitation is unlawful. Furthermore, such securities or instruments may be subject to certain regulatory and/or contractual restrictions on subsequent transfer by you, and you are solely responsible for ascertaining and complying with such restrictions. To the extent this content makes reference to a fund, the Fund may not be publicly offered in any Latin American country, without previous registration of such fund’s securities in compliance with the laws of the corresponding jurisdiction. Public offering of any security, including the shares of the Fund, without previous registration at Brazilian Securities and Exchange Commission–CVM is completely prohibited. Some products or services contained in the materials might not be currently provided by the Brazilian and Mexican platforms.

References to “J.P. Morgan” are to JPM, its subsidiaries and affiliates worldwide. “J.P. Morgan Private Bank” is the brand name for the private banking business conducted by JPM.

This material is intended for your personal use and should not be circulated to or used by any other person, or duplicated for non-personal use, without our permission. If you have any questions or no longer wish to receive these communications, please contact your J.P. Morgan team.

© 2020 JPMorgan Chase & Co. All rights reserved.